Thanks @mtom
The key for me here is the "Upside risk to our valuation", i.e. things that would push the PT beyond $5.80:
- Tasly deal
- Label extension for Ryoncil
- ARDS for US only; royalties only and no upfront or milestones from a potential deal for this indication
- +++
Also, we won't be short of news with the following short term catalysts:
- Ryoncil approval & launch
- Phase 2/3 trial for Remestemcel-L in COVID-19 patients
- LVAD Phase 3 trial
- Readouts and partnerships for CHF & CLBP
- BP forgotten COVID-19 with Temcell for Japan & Remestemcel-L for other countries
A very busy time for Mesoblast, alternative treatment options for patients and for SHs an extremely exciting time to sit back and enjoy the ride
WFH - he'd be constantly on the phone and video conferences
No wonder SI looked buggered in his last Video - but, it is a great problem to have
GLTASHs
- Forums
- ASX - By Stock
- MSB
- Bell Potter Daily Pack 16 April 2020
Bell Potter Daily Pack 16 April 2020, page-13
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.40 |
Change
-0.065(4.44%) |
Mkt cap ! $1.589B |
Open | High | Low | Value | Volume |
$1.45 | $1.46 | $1.37 | $7.886M | 5.626M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 40950 | $1.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 11456 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 43028 | 1.395 |
7 | 51954 | 1.390 |
9 | 156420 | 1.385 |
5 | 36098 | 1.380 |
7 | 343873 | 1.375 |
Price($) | Vol. | No. |
---|---|---|
1.400 | 9714 | 9 |
1.405 | 11122 | 7 |
1.410 | 77003 | 6 |
1.415 | 73398 | 7 |
1.420 | 108932 | 8 |
Last trade - 15.03pm 09/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online